Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Go back to Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $199.71 | 52 Week Low | $223.02 | |||
| Day High | $199.71 | P/E | 25.57 | |||
| Day Low | $199.71 | EPS | $7.81 | |||
| Volume | 2,261 | |||||
